Owlet Inc to Address FDA Letter Conference Call Transcript
Good morning and thank you for joining us today. This is Kurt Workman, Owlet's CEO and Co-Founder. Earlier today, Owlet submitted an 8-K filing regarding a recent communication received from the US Food and Drug Administration. This document can be found on the company's website at www.investors.owletcare.com.
Before we get started I would like to remind everyone that certain matters will be discussed in today's conference call and any forward-looking statements are subject to risks and uncertainties relating to future events and/or the future financial performance of the company. Actual results could differ materially from those anticipated in these forward-looking statements.
The risk factors that may affect results are detailed in the company's most recent public filings with the US Securities and Exchange Commission, including its final prospectus on Form 424B3 filed with the SEC on August 24, 2021, which can be found on its website at investors.owletcare.com, or
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
